These findings, like ours that showed effective treatment of HFD nephropathy using the JAK-STAT inhibitor (methotrexate), support the involvement of the JAK-STAT pathway in HFD-related chronic kidney disease. This evidence concerns the gene SOAT1 and kidney disorder.